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ABSTRACT
We have developed a PCR-based short interfering
RNA (siRNA) quantification method based on com-
petition between siRNA and a homologous DNA
primer for annealing to template DNA, avoiding the
requirement for prior conversion of RNA to cDNA.
Primers and probe were designed to amplify regions
of the human papillomavirus E6 or enhanced green
fluorescent protein genes. Having confirmed siRNA
could not act as primer for amplicon generation,
the lowest competing primer concentration yield-
ing a linear relationship between template DNA
amount (0.1–50ng) and cycle of threshold (Ct)
was determined (6.25nM). Under these conditions
addition of sequence-specific siRNA to the competi-
tive quantitative PCR (cqPCR), resulted in a dose-
dependent linear increase in Ct value. 2’-O-methyl
ribose-modified siRNA retained an ability to inhibit
template amplification in serum, unlike unmodified
siRNAs that were susceptible to endonucleases.
Mismatch-bearing or truncated siRNAs failed to
inhibit template amplification confirming sequence
specificity and an ability to discriminate between
degraded and non-degraded siRNA sequences.
Following delivery of E6 siRNA to C33-A cells
using oligofectamine or His6 reducible polymers,
siRNA uptake was quantified by cqPCR, revealing
dose-dependent uptake. We anticipate that cqPCR
will allow accurate determination of siRNA pharma-
cokinetics following in vivo delivery, greatly facili-
tating development of therapeutic siRNA delivery
strategies.
INTRODUCTION
RNA interference (RNAi) is an evolutionarily conserved
process involved in physiological regulation and patho-
gen defence, in which double-stranded RNA induces
sequence-speciﬁc gene silencing through chromatin remo-
delling, inhibition of protein translation or direct mRNA
degradation (1–3). RNAi is facilitating our understand-
ing of functional genomics and oﬀers potential for therapy
by targeting disease-associated genes (4,5). The simplest
way to induce an RNAi response is to deliver short inter-
fering RNA (siRNA) directly into target cells utilizing
the endogenous silencing machinery of the microRNA
(miRNA) pathway. In order to improve therapeutic
siRNA pharmacokinetics, through chemical modiﬁcations
or improved vector design, there is a requirement to
obtain a detailed assessment of uptake into various tissues
following in vivo delivery.
Methods of siRNA detection within cells, based on
liquid hybridization with a
32P-labelled probe followed
by nuclease protection, are highly sensitive capable of
detecting in the order of 10–100 attomol of siRNA (6).
However, this approach is indirect and not all labora-
tories are set up to deal with radioactive methodologies.
Fluorescence-based methods while useful for detection of
siRNA uptake into cells are not amenable for quantiﬁca-
tion (7,8). Furthermore detection methods which rely on
indirect labelling technology may be misleading due to
diﬀerential rates of catabolism of label and siRNA. It is
therefore desirable to develop alternative speciﬁc, sensitive
non-radioactive quantiﬁcation methods, ideally able to
measure only intact functional siRNA.
Real time or quantitative PCR (qPCR) through cyclical
ampliﬁcation of template enables quantiﬁcation of speciﬁc
nucleic acid sequences with a high degree of precision.
Sequence-speciﬁc Taqman probes carrying a ﬂuorophore
and quencher dye at each end are cleaved by the 50-t o
30-exonuclease activity of Taq DNA polymerase during
the annealing/extension phase of PCR, releasing a ﬂuores-
cent signal proportional to the amount of accumulated
PCR product (9). A variety of oligonucleotides can be
quantiﬁed, however detection of siRNA by conventional
qPCR is not feasible, since molecules commonly 19–25nt
in length are too small to anneal with primers and gener-
ate amplicons. Instead alternative PCR-based methods
have been developed including primer extension (PE)
(10), the invader assay (11), stem–loop RT-PCR (12),
ligation assay (13) and crook hairpins (14) (Figure 1a).
Stratford et al. (15) compared PE RT-PCR, ligation
qPCR and stem–loop RT-PCR methodologies to detect
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They concluded that the ligation and PE RT-PCR meth-
ods required lengthy optimization and were poor at dis-
criminating truncated (representing degraded) siRNAs,
while the stem–loop RT-PCR had lower background
and could eﬀectively discriminate between full length
and truncated sequences. Furthermore, they adapted the
method of Chen et al. (12) which employed a sequence-
speciﬁc probe, by using a universal Taqman probe, saving
development time and costs. However, these methods rely
on the use of two-stage reactions, with expensive and time-
consuming reverse-transcription steps required to create
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Figure 1. PCR-based methods of siRNA and miRNA quantiﬁcation. (a) The PE assay relies on two reactions; the ﬁrst involves a gene-speciﬁc primer
to convert RNA to cDNA, introduces a universal PCR binding site to one end and extends the length of the cDNA. In the second reaction, cDNA is
ampliﬁed when combined with a reverse primer containing locked nucleic acids (LNA) possessing a 20-O,40-C-methylene bridge to stabilize the sugar
group and increase hybridization aﬃnity of oligonucleotides and a generic universal primer common to all assays; ampliﬁcation monitored by SYBR
green ﬂuorescence (10). The invader assay is dependent on the formation of a complex between a target nucleic acid hybridizing to both a probe and
an invasive oligonucleotide in an overlapping manner. The probe then undergoes enzymatic cleavage by a structure-speciﬁc nuclease, cleavase to
release the 50-ﬂap. In a second reaction the released ﬂap hybridizes to a secondary reaction template which also hybridizes an overlapping FRET
oligo, cleavage of which generates a ﬂuorescent signal. An arrestor oligo added to the reaction sequesters any unreacted probe preventing binding to
the secondary reaction template (11). Jiang et al. (14) utilized a bi-functional siRNA construct in which the 30-end of the sense strand of siRNA was
modiﬁed with a nuclease-resistant DNA hairpin. The ‘crook siRNA’ acts both as a primer for PCR ampliﬁcation of an engineered DNA template
whilst retaining silencing activity (14). The ligation assay uses ligation of 50- and 30-oligos containing sites for the M13 forward and reverse primers
followed by qPCR ampliﬁcation with M13 primers (13). The stem–loop RT-PCR assay of Chen et al. (12) employs a stem–loop primer binding to
the 30-end of the siRNA. Reverse transcriptase then extends the cDNA (12). Ampliﬁcation occurs using a gene-speciﬁc forward primer, universal
reverse primer and speciﬁc probe. Stratford et al. (15) adapted the assay by using a universal probe to reduce time and costs. (b) Conventional qPCR
Taqman probes rely on the 50–30 nuclease activity of Taq DNA polymerase to cleave a dual-labelled probe during hybridization to the comple-
mentary target sequence. Our modiﬁed cqPCR method relies on the use of a primer competing with the siRNA sense strand to bind to a
complementary region of template DNA resulting in decreased PCR product and increased Ct value. For diagrammatic purposes template DNA
strands are shown in opposite orientation to convention. Dotted arrow indicates the direction of polymerization which is inhibited in the presence of
the competing siRNA molecule.
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approach would be to quantify all unmodiﬁed siRNAs
in a single existing qPCR reaction.
Competitive qPCR (cqPCR), like conventional qPCR,
is used to estimate target gene concentration in a sample
by comparison with standard curves constructed from
ampliﬁcation of serially diluted DNA standards. For
cqPCR, an internal competitor DNA is added at known
concentration to serially diluted standards and the
unknown samples. Following co-ampliﬁcation the ratio
of internal competitor and target PCR products are calcu-
lated for both the standards and the unknown samples,
and a standard curve generated plotting competitor–target
PCR ratios against initial target DNA concentration of
the standard dilutions (16–18). We wished to determine
whether the cqPCR method could be modiﬁed, so that
siRNA competes with the forward primer to anneal to a
homologous region on target DNA (Figure 1b). In con-
ventional qPCR, the primers and probe are present in
excess, however in our modiﬁed cqPCR method the
concentration of forward primer was carefully regulated
to be at limiting concentration, so that competition by
siRNA binding to the template would proportionally
decrease the number of PCR products formed.
MATERIALS AND METHODS
Cell culture
CaSki human cervical epithelial carcinoma cells, contain-
ing approximately 600 copies of the human papilloma-
virus 16 (HPV16) genome, were maintained in RPMI-
1640 medium (Invitrogen, Paisley, UK) supplemented
with 10% (v/v) fetal calf serum (FCS), 10mM HEPES,
50U/ml penicillin and 50mg/ml Streptomycin
(Invitrogen). SiHa human cervical squamous cell carci-
noma cells containing 1–2 integrated copies of the
HPV16 genome were maintained in Dulbecco’s modiﬁed
eagle medium (DMEM) (PAA Laboratories GmbH,
Yeovil, UK) supplemented with 10% FCS, 1.0mM
sodium pyruvate, 0.1mM non-essential amino acids, 50
U/ml penicillin and 50mg/ml streptomycin. C-33A
human cervical carcinoma cells lacking HPV DNA, were
maintained in Minimal Essential Medium (MEM) (Eagle)
(PAA Laboratories GmbH) supplemented with 10% FCS,
1.0mM sodium pyruvate, 0.1mM non-essential amino
acids, 50 U/ml penicillin and 50mg/ml streptomycin. PC-
3 metastatic human prostate carcinoma cells were main-
tained in Dulbecco’s Minimal Essential Medium
(DMEM) containing 10% FCS, 2mM glutamine, 50 U/
ml penicillin and 50mg/ml streptomycin (Invitrogen).
Nucleic acids
The siRNAs targeting HPV16 E6 termed E6-siRNA-1
(sense: 50-GAGCUGCAAACAACUAUACtt-30, anti-
sense: 50-GUAUAGUUGUUUGCAGCUCtt-30), E6-
siRNA-2 (sense: 50-GAGGUAUAUGACUUUGCUU
tt-30, antisense; 50-AAGCAAAGUCAUAUACCACt
t-30), E6-siRNA-1-17mer (sense: 50-UGCAAACAACUA
UACtt-30, antisense; 50-GUAUAGUUGUUUGCAtt-30),
E6-siRNA-1-13mer (sense: 50-AACAACUAUACtt-30,
antisense; 50-GUAUAGUUGUUtt-30), E6-siRNA-1-mis-
match#1 (sense: 50-GAGCUAGCAACAACUAUACtt-30,
antisense; 50-GUAUAGUUGUUGCUAGCUCtt-30),
E6-siRNA-1-mismatch#2 (sense: 50-GACCUGCAAAG
AACUAUUCtt-30, antisense; 50-GAAUAGUUCUUUG
CAGGUCtt-30), mismatches shown in italics; enhanced
green ﬂuorescent protein (EGFP) (sense: 50-GCGCUAU
GACGGCAAUAAAtt-30, antisense; 50-UUUAUUGCC
GUCAUAGCGCtt-30) and ﬁreﬂy luciferase (GL-3)
(sense: 50-CUUACGCUGAGUACUUCGAtt-30, anti-
sense: 50-UCGAAGUACUCAGCGUAAGtt-30) were
synthesized by Applied Biosystems (Warrington, UK).
20-O-methyl chemically modiﬁed siRNA targeting
HPV16 E6 termed 20-O-Me-E6-siRNA-1 (sense: 50-mG
AmGCmUGmCAmAAmCAmACmUAmUAmCtt-30,
antisense; 50-GmUAmUAmGUmUGmUUmUGmC
AmGCmUCtt-30) was also synthesized by Applied
Biosystems.
Genomic DNA was extracted from CaSki cells using the
QiaAMP DNA mini kit (Qiagen, Crawley, UK) in the
absence of RNase according to the manufacturer’s instruc-
tions. A commercially available plasmid, pEGFPC1
(Clontech, Whitchurch, UK) was grown in Escherichia
coli HB101 competent bacteria and extracted using an
EndoFree Plasmid Mega kit (Qiagen) in the absence of
RNase according to the manufacturer’s instructions.
qPCRand cqPCR
The qPCR was performed using various primer/probe
sets. For assays involving E6-siRNA-1, E6-siRNA-2,
E6-siRNA-1-17mer, E6-siRNA-1-13mer, E6-siRNA-1-
mismatch#1, E6-siRNA-1-mismatch#2 and 20-O-Me-E6-
siRNA-1, the E6-forward primer: 50-gagctgcaaacaactat
actt-30, E6-reverse primer: 50-cccgaaaagcaaagtcatatacct-30
and FAM-labelled probe: 50-tcgcagtaactgttgcttgcagtacac
acat-30 were used (Sigma-Genesis, Wimborne, UK). For
assays involving EGFP-siRNA, the forward primer: 50-
gcgctatgacggcaataaa-30, reverse primer: 50-aaccccgcgtttat-
gaaca-30 and FAM-labelled probe: 50-aataaaacg-
cacggtgttgggtc-30 were used (Sigma-Genesis). In each
instance the underlined residues in the primers represent
thymidine residues, substituted for uracil residues in the
corresponding competing siRNAs. Template DNA con-
taining the HPV16 E6 ORF from CaSki cell extracts was
ampliﬁed using the standard thermal cycling conditions;
508C for 2min, 958C for 10min, followed by 45 cycles of
958C for 15s and 608C for 45s. Variations to the E6 stan-
dard reaction included lowering the annealing/extension
phase temperature from 608Ct o5 0 8Co r4 5 8C. The reac-
tion conditions were generated in an Applied Biosystems
7000 Sequence Detection System and subsequent analysis
performed using ABI Prism 7000 SDS software.
The standard ampliﬁcation reaction contained Platinum
qPCR supermix (which includes 60 U/ml Taq DNA
Polymerase, 40mM Tris–HCl (pH 8.4), 6mM MgCl2,
400mM dGTP, 400mM dATP, 400mM dCTP, 800mM
dUTP, 40 U/ml uracyl DNA glycosylase and 1mM ROX
passive reference dye) (Invitrogen), to which was added
200nM forward primer, 200nM reverse primer and
100nM probe. The amount of template DNA from
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pEGFP was used.
For development of cqPCR, the standard reaction
was subsequently modiﬁed to contain between 3.125nM
and 200nM forward primer, while the amount of
E6-containing template DNA was varied from 0.1ng to
50ng. Unless otherwise stated competition assays were
performed using 6.25nM forward primer, 200nM reverse
primer and 100nM probe; or 200nM forward primer,
6.25nM reverse primer and 100nM probe. siRNA was
added at concentrations ranging from 3.125nM to
400nM (208pg to 26.6ng) by dilution with nuclease
free water. The temperature of the annealing/extension
phase of the reaction was 508C for E6-based assays and
558C for EGFP.
Cell-based cqPCR assays
For studies in the presence of cell lysate, 3 10
6C-33A
cells were lysed with 300ml of 20mM Tris–HCl pH 8.5,
0.5% NP-40, 20mg/ml tRNA buﬀer for 15min at 808C
and centrifuged to remove debris. E6-siRNA was seri-
ally diluted in lysis buﬀer and spiked into the C-33A cell
lysate (normalized for total protein), such that the siRNA
concentration ranged from 3.125nM to 200nM. Five
microlitres of lysate was then added to cqPCRs con-
taining between 6.25nM and 75nM forward primer and
200nM reverse primer. Reactions containing 50nM
forward primer and 400nM reverse primer were also
examined.
To quantify the uptake of E6-siRNA when complexed
with Oligofectamine (Invitrogen) or His6 reducible
polycations prepared as previously described (19,20),
10
6C-33A cells were seeded into the wells of a 6-well
plate 24h prior to delivery. Three microlitres of Oligo-
fectamine was added to 12ml of Opti-MEM I medium
(Gibco, Paisley, UK) in one vial and 3mlo f2 0 mM E6-
siRNA-1 added to 50ml of Opti-MEM I medium in a
second vial. The siRNA and Oligofectamine were then
mixed and incubated for 20min, prior to the addition of
32ml of Opti-MEM I medium. His6 RPC/siRNA poly-
plexes were prepared at w/w 40 (N:P, 15:1). E6-siRNA
complexes were then added to cells in wells containing
500ml of serum-free culture medium to give a ﬁnal
siRNA concentration of 25nM, 50nM, 100nM or
200nM. As an additional control E6-siRNA-1/Oligofecta-
mine complexes were added to wells lacking cells at a
concentration of 25nM or 200nM. After 4h the cells or
‘no cell’ wells were washed with PBS and lysis buﬀer
added as described above. The siRNA was quantiﬁed by
the addition of 5ml of cell lysate to cqPCR and correla-
tion with a standard curve generated by spiking mock-
treated lysed cells with known amounts of siRNA. The
assay was repeated three times using C33-A cells and
once using PC-3 cells. Further controls were performed
with E6-siRNA-1 complexed with Oligofectamine added
directly to cqPCRs (containing 6.25nM forward primer,
200nM reverse primer and 100nM probe) at 3.125–
200nM ﬁnal concentration for comparison with uncom-
plexed siRNA.
EGFP transfection assay
SiHa cells were plated at 10
5 cells per well (24-well plate)
24h prior to transfection. pEGFPC1 was mixed with
siGFP or siLUC and added to DOTAP liposomal
transfection reagent (Avanti Polar Lipids, Alabaster,
AL, USA) at w/w 5:1 (DOTAP:nucleic acids) according
to the manufacturer’s instructions. Complexes were added
to cells such that each well received 200ng DNA and
10nM siRNA. Control wells were transfected with
pEGFPC1 alone or mock transfected. EGFP expression
was analysed after 24h by ﬂow cytometry using a Becton
Dickinson FACSCalibur and CellQuest Pro software.
RESULTS
siRNA doesnot function as aprimer
We chose to explore the competitive assay system through
ampliﬁcation of the human papillomavirus 16 E6 (HPV16
E6) and EGFP genes. E6 is a viral oncogene that leads to
p53-mediated degradation and is implicated in cervical
neoplasia. We have previous designed siRNA to target
this gene (E6-siRNA-1) for treating cervical carcinoma
(Liu W.L. et al., submitted for publication). Template
target DNA was obtained from the CaSki human cervical
carcinoma cell line containing approximately 600 copies of
the HPV 16 genome. For EGFP template DNA, we used
the EGFP expression plasmid pEGFPC1 (Clontech).
qPCR primers and probe were designed to amplify a
93-bp region of the HPV16 E6 gene. The forward primer
was designed to be in competition with the sense strand
of an E6-targeting siRNA (E6-siRNA-1), to hybridize to
a homologous region of the template DNA. The E6
forward primer contains three thymidine residues which
are replaced by three uracil residues in the sense strand of
the E6 siRNA. For siRNA to function as a competitor
molecule, it is important it cannot itself perform as a
primer for template polymerization. Ampliﬁcation of the
E6 gene from a CaSki cell genomic DNA template was
compared using conventional qPCR containing excess
forward primer (200nM), with a reaction lacking for-
ward primer but containing 200nM E6-siRNA-1. As
expected only reactions containing sequence-speciﬁc
forward primer-generated PCR products with those
containing siRNA fail to amplify the template after 45
cycles (Figure 2).
Optimization ofcqPCR
Prior to performing cqPCR studies it was necessary to
optimize, the amount of template DNA, the concentration
of the forward primer and the temperature of the anneal-
ing/extension phase of the reaction. Using conventional
qPCR containing excess primers and probe, there was a
linear relationship between the amount of template
DNA, ranging from 1pg to 100ng, and the threshold of
cycle (Ct) value (Figure 3a). For competition studies, Ct
values should be less than 25 to provide scope for an
increase in Ct in the presence of competing siRNA. A
Ct value of 25 related to 1ng of template CaSki genomic
DNA, while the use of 100ng DNA generated a large
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complementary product strands (21) manifested as a
decrease in product towards the end of the reaction
(Figure 3a). Consequently, the amount of template
CaSki genomic DNA for competition studies should be
>1ng but <100ng.
To maximize the changes in Ct value on addition of
competing siRNA, it was necessary to determine the
lowest concentration of forward primer permissive for
eﬃcient gene ampliﬁcation. Reactions were tested con-
taining between 3.125nM and 200nM forward primer,
with reverse primer maintained at 200nM in each case.
At an annealing/extension temperature of 608C all reac-
tions generated PCR products, however the amount of
PCR product fell as the concentration of the forward
primer became limiting (Figure 3b, left panel). When the
annealing/extension temperature was reduced to 508Co r
458C, the amount of PCR products at low primer concen-
trations increased.
To determine that the modiﬁed reaction would still
generate a linear relationship between the amount of
CaSki genomic DNA template and Ct value, eﬃciency
of ampliﬁcation was further examined using a range of
forward primer concentrations and between 0.1ng
and 50ng template DNA (Figure 3c). A slope of  3.322
indicates 100% PCR eﬃciency, where the amount of
PCR product doubles every cycle. At 508C, ampliﬁcation
eﬃciency decreased sharply below 6.25nM forward
primer, while at 458C, the ampliﬁcation eﬃciency dropped
below 12.5nM. Based on these ﬁndings, for subsequent
competition assays we employed a 508C annealing/
extension temperature, a 6.25nM forward primer con-
centration and 45ng of template CaSki genomic DNA.
siRNA competes withprimers facilitating quantification
The eﬀect of adding E6-siRNA-1 on E6 ampliﬁcation was
examined by cqPCR. Increasing siRNA concentration
resulted in an increase in Ct value in a linear manner
(Figure 4a) conﬁrming inhibition of ampliﬁcation. The
lowest siRNA concentration tested was 3.125nM corre-
sponding to 208pg. In contrast, a non-speciﬁc siRNA
control with no homology to the HPV16 E6 forward
primer, had no eﬀect on E6 ampliﬁcation (Figure 4b).
We then designed and tested a second siRNA targeting
HPV16 E6 mRNA (E6-siRNA-2), but this time with
homology to the reverse primer. Various amounts of E6-
siRNA-2 were added to reactions containing 6.25nM
reverse primer and 200nM forward primer, again result-
ing in a proportional increase in Ct value with siRNA
concentration (Figure 4c).
To conﬁrm the widespread application of this technique,
we designed a new set of primers and probe to amplify an
89-bp region of the EGFP gene. The plasmid nature of the
template resulted in employing 4500-fold less DNA in the
reaction, compared to the genomic DNA template. In
order to generate a linear relationship between plasmid
template amount and Ct value, the annealing temperature
of the reaction was raised to 558C, whilst the other condi-
tions were maintained as described above. We then
designed a siRNA with homology to the forward EGFP
primer, obtaining 70% knockdown in EGFP expression
following transient transfection of SiHa cells (data not
shown). The addition of various amounts of EGFP-
siRNA to the cqPCR reaction containing homologous for-
ward primer, once again resulted in a linear relationship
between Ct value and siRNA concentration (Figure 4d).
Since therapeutically active siRNA molecules require
chemical modiﬁcation to provide protection from serum
endonucleases, we tested whether E6-siRNA-1 modiﬁed
with the 20-O-methyl ribose modiﬁcation retained an
ability to compete with a homologous primer. The data
showed there was a linear relationship between chemically
modiﬁed siRNA concentration and Ct value (Figure 4e).
When the siRNA was mixed with 10% FCS prior to addi-
tion to cqPCRs, the unmodiﬁed siRNA failed to inhibit
template ampliﬁcation presumably due to degradation by
serum endonucleases (Figure 4f). However, the siRNA
carrying the 20-O-methyl ribose modiﬁcations generated
a linear increase in Ct value with siRNA dose, conﬁrming
protection from endonuclease digestion and an ability to
be quantiﬁed in a clinically relevant biological sample.
To conﬁrm speciﬁcity of the competition reaction, we
tested truncated or mismatched siRNAs. Both a 13mer
and 17mer E6-siRNA-1 (both truncated at the 50-end)
lost the ability to compete with the forward primer
(Figure 4g), suggesting that the cqPCR technique can dis-
criminate between intact and degraded siRNAs. Finally
two E6-siRNAs, each possessing three mismatches with
the forward primer, also failed to compete with the for-
ward primer (Figure 4h) conﬁrming the speciﬁcity of the
cqPCR. These results conﬁrm that siRNA can compete
with homologous primers in a sequence-speciﬁc and
concentration-dependent manner that permits siRNA
quantiﬁcation.
Quantification of siRNA from spiked cell lysate
Having shown that the cqPCR was functional in a cell-free
system, we tested whether siRNA could be quantiﬁed in
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Figure 2. siRNA cannot mediate polymerization in the absence of
forward primer. Ampliﬁcation proﬁle A from qPCR containing 100ng
template DNA extracted from CaSki cells, 200nM E6 forward primer,
200nM E6 reverse primer and 100nM E6 probe. Proﬁle B indicates
reactions prepared as in A except for the lack of forward primer, but
containing 200nM E6-siRNA-1, which binds to the same region of
DNA as the forward primer. Reactions were performed in triplicate.
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Figure 3. Optimization of qPCR components prior to competition assays. (a) Linear relationship between template DNA amount and Ct value. Left
panel illustrates ampliﬁcation proﬁles from qPCR performed using (i) 100ng, (ii) 10ng, (iii) 1ng, (iv) 0.1ng, (v) 0.01ng or (vi) 0.001ng template
CaSki cell genomic DNA; proﬁle (G) indicates water blank. All reactions contained 200nM E6 forward and reverse primers and 100nM E6 probe.
Right panel shows the linear relationship between the cycle at which the threshold was crossed (Ct) and the amount of template DNA. The slope of
the line indicates the eﬃciency of the reaction. (b) Eﬀect of forward primer concentration and the annealing/extension phase temperature on Ct value.
Reactions were performed using (i) 200nM, (ii) 100nM, (iii) 50nM, (iv) 25nM, (v) 12.5nM, (vi) 6.25nM or (vii) 3.125nM E6 forward primer, with
200nM E6 reverse primer and 100nM E6 probe in each case. Reactions were performed using a 608C (left panel), 508C (middle panel) or 458C
(right panel) annealing/extension phase. (c) Eﬀect of primer concentration on ampliﬁcation eﬃciency. Reactions were performed using either a 508C
or 458C annealing/extension phase and E6 forward primer concentrations ranging from 3nM to 200nM. The amount of template DNA ranged
from 0.1ng to 50ng. The eﬃciency of ampliﬁcation is indicated by the slope and degree of linearity illustrated by the R
2 value. All reactions were
performed in triplicate.
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siRNA entry into mammalian cells. Known amounts
of E6-siRNA-1 were spiked into cell lysate and added to
a cqPCR reaction containing 6.25nM forward primer
concentration and 25ng template. Template ampliﬁcation
was attenuated in the presence of cell lysate [Figure 5a,
compare panels (i) and (iv)]. Raising the concentration
of the forward primer from 6.25nM to 75nM resulted
in an increase in template ampliﬁcation (Figure 5a,
panels iv–viii). Reactions containing 50nM or 75nM
forward primer generated the greatest range of Ct values
between the lowest and highest competing siRNA concen-
trations. Increasing the concentration of reverse primer
from 200nM to 400nM, with 50nM forward primer,
resulted in an acceptable linear relationship between
Ct value and log 10 siRNA concentrations [Figure 5a,
panel (ix) and Figure 5b].
Quantification of siRNA from lysates of transfected cells
Finally, we delivered E6-siRNA to C-33A cells using
either the commercially available lipid Oligofectamine,
or a reducible polymer based on CH6K3H6C monomers
(20). Following a 4h incubation, the cells were washed
and lysed, and the siRNA uptake quantiﬁed by cqPCR
using a standard curve prepared by spiking cell lysate
with known amounts of E6-siRNA. The experiment was
performed on three separate occasions, the results shown
in Figure 6 and Table 1 typical of one such experiment.
For both Oligofectamine and His6 RPC the amount of
siRNA detected inside cells increased with the dose
administered (Figure 6 and Table 1). For Oligofectamine
this ranged from 10% to 30% of input dose, while
for His6 RPC it was 13–100% (Table 1), delivery being
more eﬃcient at the highest vector dose. All siRNA
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Figure 4. The presence of siRNA inhibits ampliﬁcation of template DNA in a sequence-speciﬁc and concentration-dependent manner. Various
amounts of (a) E6-siRNA-1 from 3.125nM to 400nM or (b) non-speciﬁc luciferase siRNA from 1.56nM to 200nM were added to cqPCR containing
6.25nM E6 forward primer, 200nM E6 reverse primer and 100nM E6 probe. (c) 3.125nM–400nM E6-siRNA-2 was added to cqPCR containing
200nM E6 forward primer, 6.25nM E6 reverse primer and 100nM E6 probe. (d) 3.125nM–100nM EGFP-siRNA was added to cqPCR containing
6.25nM EGFP forward primer, 200nM EGFP reverse primer and 100nM EGFP probe. (e) 3.125nM–200nM E6-siRNA-1 (square symbols, solid
line) or 20-O-methyl-E6-siRNA-1 (triangle symbols, dashed line) was added to cqPCR containing 6.25nM E6 forward primer, 200nM E6 reverse
primer and 100nM E6 probe. (f) 3.125nM–200nM E6-siRNA-1 (square symbols, solid line) or 20-O-methyl-E6-siRNA-1 (triangle symbols, dashed
line) was added 10% FCS prior to addition to cqPCR containing 6.25nM E6 forward primer, 200nM E6 reverse primer and 100nM E6 probe. (g)
3.125nM–200nM E6-siRNA-1 (solid line), E6-siRNA-1-17mer (dashed line) or E6-siRNA-1-13mer (dotted line) were added to cqPCR containing
6.25nM E6 forward primer, 200nM E6 reverse primer and 100nM E6 probe. (h) 3.125nM–200nM E6-siRNA-1 (solid line), E6-siRNA-1-mis-
match#1 (dashed line) or E6-siRNA-1-mismatch#2 (dotted line) were added to cqPCR containing 6.25nM E6 forward primer, 200nM E6 reverse
primer and 100nM E6 probe. All reactions were performed in triplicate.
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merely stuck to the plastic, since blank wells without cells
which were spiked with 25nM or 200nM E6-siRNA-1
in complex with Oligofectamine-generated Ct values
that were not signiﬁcantly diﬀerent from cqPCRs
lacking siRNA (data not shown). The ability of siRNA
to inhibit DNA template ampliﬁcation was not aﬀected
by complexation with Oligofectamine per se, since the
addition of E6-siRNA-1 alone or in complex to cqPCRs
in the absence of cell lysate generated virtually the
same slope and R
2 values (data not shown). Delivery of
E6 siRNA using Oligofectamine to C33-A cells was per-
formed on three separate occasions and once to PC-3
cells (data not shown). The results shown in Figure 6
and Table 1 are illustrative of one experiment involving
C33-A cells, however in each study there was a dose-
dependent increase in the amount of internalized siRNA
conﬁrming the reproducibility of the assay. The level of
variability in Ct value (approximately three Ct units)
appeared greater at the highest (200nM) siRNA con-
centration, with lower concentrations generating more
reproducible results.
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Figure 5. siRNA can inhibit template ampliﬁcation in the presence of cell lysate. (a) siRNA was diluted in C-33A cell lysate or water and added at a
ﬁnal concentration of 3.125–200nM to cqPCRs containing various concentrations of forward primer (FP) and reverse primer (RP) as indicated. In
each case the x-axis represents number of cycles and the y-axis the relative level of ﬂuorescence. (b) Linear relationship between Ct value and log 10
of E6-siRNA-1 concentration for reactions containing 50nM forward primer/400nM reverse primer in the absence (top graph) or presence (bottom
graph) of cell lysate. Square symbols and solid lines, E6-siRNA-1; triangle symbols and dashed line, luciferase siRNA.
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Figure 6. Quantiﬁcation of E6-siRNA uptake into C-33A cells when complexed with Oligofectamine or His6 reducible polycations. E6-siRNA
complexes were added to cells at 25nM, 50nM, 100nM or 200nM ﬁnal concentration in triplicate as indicated. Using a standard curve generated by
spiking cell lysate with known amounts of E6-siRNA and then added to cqPCR, the amount of siRNA taken up by the cells was determined. The
amount of siRNA in complex with Oligofectamine that was delivered to cells was assessed in three independent experiments, the results of one such
experiment is shown here.
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The ability to accurately determine siRNA pharmaco-
kinetics following in vivo delivery is highly desirable for
the development of therapeutic siRNA vectors. Indeed,
the interpretation of any siRNA silencing assay would
be facilitated by quantiﬁcation of uptake. In this manner
it would be possible to study tissue distribution in order
to evaluate tissue targeting strategies and siRNA stability.
Our novel cqPCR method based on siRNA directly
competing with a homologous DNA primer at limited
concentration, and thus interfering with template DNA
ampliﬁcation, results in a linear relationship between
siRNA concentration and Ct value.
In order for the cqPCR method to function it was
important to demonstrate that the heat denatured siRNA
strands cannot function as primers for DNA template
ampliﬁcation. Shibata et al. (22) showed that the ability
of RNA to act as a primer in PCR is dependent upon the
DNA polymerase employed. They reported Sequenase v.
2.0 DNA polymerase (Amersham) and rTth DNA poly-
merase (Perkin-Elmer Cetus) mediated chain elongation
from an RNA primer, whereas AmpliTaq DNA polymer-
ase (Perkin-Elmer Cetus) did not. Stump et al. (23) showed
that the ability of 20-O-Me RNA oligonucleotides to prime
DNA synthesis using Taq polymerase was dependent
on the inclusion of a minimum of six DNA residues at
the 30-end. Therefore, our results demonstrating lack of
template ampliﬁcation from a siRNA primer using Taq
polymerase are in agreement with these observations.
To enable siRNA quantiﬁcation it was necessary
that the competing DNA primer concentration, present
in excess in conventional qPCR, was reduced. However,
the primer concentration must be suﬃcient to maintain
ampliﬁcation eﬃciency. Reduction of the forward primer
to a concentration of 6.25nM, using a 508C annealing/
extension phase, maintained a linear relationship between
DNA template amount and Ct value (R
2=0.989), with
a PCR eﬃciency of 93.18% [%eﬀ=(10
 1/ 3.4967)
 1 100%]. Following addition of varying amounts
of E6-siRNA-1 to reactions containing 45ng template
DNA, we obtained an acceptable relationship between
Ct value and siRNA concentration (E6-siRNA-1,
R
2 value=0.986). The robustness of the cqPCR assay
was conﬁrmed by using diﬀerent siRNAs to compete
with diﬀerent primers (E6-siRNA-2, R
2 value=0.986;
EGFP-siRNA, R
2 value=0.947). The standard cqPCR
conditions (including the forward and reverse primer
and probe concentrations), between the three siRNAs
tested in the two template systems (E6 and EGFP) were
the same, requiring only a change in temperature for the
annealing/extension phase of the reaction based on
the melting temperature of the components involved,
and the amount of template DNA employed, dependent
on whether plasmid or genomic DNA was used. As a
result the amount of optimization required between dif-
ferent siRNAs is minimal. The sequence-speciﬁc nature
of the assay was conﬁrmed using irrelevant siRNA target-
ing luciferase or E6 targeting siRNAs bearing three
mismatches, since on each occasion the Ct value was unaf-
fected by the presence of the siRNA.
We demonstrated that both sense (E6-siRNA-1) and
antisense (E6-siRNA-2) siRNA strands can be detected.
It is not clear whether association of siRNA with RNAi-
induced silencing complex (RISC) prevents binding to
template DNA during cqPCR. If so, although not exam-
ined here, it could be possible by designing suitable pri-
mers and probes to determine the relevant amount of
sense and antisense strands; diﬀerences reﬂecting diﬀer-
ential loading of strands into the RISC, thus allowing
evaluation of RNAi kinetics.
Chemical modiﬁcations to the siRNA are necessary
for protection of nuclease degradation present in the
serum during in vivo delivery. The commonly employed
20-O-methyl ribose modiﬁcation, when applied to the
E6-siRNA-1, was compatible with quantiﬁcation by the
cqPCR technique. Furthermore unlike the unmodiﬁed
siRNA, the chemically stable siRNA retained an ability
to inhibit template ampliﬁcation in the presence of serum
in a linear manner.
We attempted to determine the amount of siRNA inside
cells initially by extracting the siRNA along with other
small RNA species. However, the extraction yield in our
hands proved highly variable and was ineﬃcient at low
input doses (data not shown). We therefore attempted to
detect siRNA directly in cell lysate using a simple cell lysis
solution previously employed for the Invader assay (11).
The qPCR assay, irrespective of siRNA content, required
modiﬁcation consisting of increased forward and reverse
Table 1. Quantiﬁcation of E6-siRNA uptake into C-33A cells when complexed with Oligofectamine or His6 reducible polycations
Vector siRNA concentration added
(nM) (amount in pmol)
Mean Ct value (SD) log 10 siRNA
concentration
siRNA concentration detected
(nM) in cells (amount in pmol)
Oligofectamine 25 (15) 22.64 (1.52) 0.831 6.8 (4.1)
Oligofectamine 50 (30) 23.63 (0.61) 0.985 9.7 (5.8)
Oligofectamine 100 (60) 23.68 (1.66) 0.994 9.9 (5.9)
Oligofectamine 200 (120) 25.52 (3.10) 1.667 46.5 (27.9)
His6 RPC 25 (15) 22.82 (3.03) 0.862 7.3 (4.4)
His6 RPC 50 (30) 22.51 (0.59) 0.805 6.4 (3.8)
His6 RPC 100 (60) 25.03 (2.6) 1.597 39.5 (23.7)
His6 RPC 200 (120) 27.87 (2.7) >2.301 >200 (>120)
E6-siRNA complexes were added to cells at 25nM, 50nM, 100nM or 200nM ﬁnal concentration (amount in pmol shown in brackets) in triplicate as
indicated. The amount of siRNA taken up by the cells shown in Figure 6 was determined by comparing the mean Ct value [standard deviation (SD)
shown in brackets] with a standard curve generated by spiking cell lysate with known amounts of E6-siRNA added to cqPCR.
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ampliﬁcation. This was due to the components of the
cell lysate and not the invader assay buﬀer itself, since
lysis buﬀer alone did not aﬀect the Ct values obtained
(data not shown). Cellular proteins binding to the primers
and probe may be accountable for this eﬀect. However,
despite this, the ability of siRNA to inhibit ampliﬁcation in
a sequence-speciﬁc manner was maintained. It is possible
that some loss of assay sensitivity occurs in the presence
of cell lysate due to enzymatic or chemical modiﬁca-
tion of the siRNA or the presence of RNA-binding
proteins. However, the lowest concentration of siRNA
(E6-siRNA-1) spiked into lysate that we tested was
3.125nM, (equivalent to  200pg/ml or 16fmol/ml)
which resulted in a Ct value of 22.34; a value clearly
discriminated from background (Ct=20.32). Due to the
dilution factor created by adding the siRNA to the reac-
tion this equates to a 625 pM spike-in signal, which is
comparable to the 200 pM spike-in signal reported to be
detectable by the PE-PCR assay (10). Soutschek et al. (4)
reported that chemically modiﬁed siRNA reduced apoli-
poprotein B (apoB) expression in liver and jejunum,
resulting in a 68% decrease in the plasma level of apoB
protein and reduced total cholesterol. Administration of
50mg/kg siRNA by tail vein resulted in the accumulation
of 100–200ng/g tissue in liver and jejunum. Assuming a
liver weight of 1.5g, the lysis and re-suspension of tissue
at  1g/ml would enable siRNA detection using our
cqPCR approach. Therefore, the cqPCR assay could be
employed to monitor therapeutically meaningful siRNA
concentrations.
siRNA therapeutics are now being commercially
and clinically developed for a host of targets. However,
assays for siRNA measurement (e.g. for pharmacokinetic
studies) are usually reliant on labelled versions (e.g. radio-
active siRNA tracers) which are rapidly degraded. The
ability of the cqPCR to discriminate between truncated
siRNAs suggests that the assay will allow detection of
intact (and therefore functional molecules) and not par-
tially degraded siRNAs, a problem for label-based assays.
Our cqPCR method has advantages over existing PCR-
based methodologies in that the reaction is performed in
a single step without the need for expensive and time-
consuming conversion of RNA into cDNA prior to quan-
tiﬁcation. Although a standard curve is required adding
a few extra samples per run, the overall cost of the pro-
cedure is reduced compared to two-stage qPCR-based
methods since there is no requirement for reverse tran-
scriptase. However, the exact time and cost beneﬁt of
the cqPCR assay will vary depending upon the number
of samples being tested, with larger sample numbers gen-
erating greater savings.
The cqPCR assay has been tested here using synthesized
siRNA molecules, however we envisage that the technique
could be adapted to analyse siRNAs generated from
shRNA expression vectors. Furthermore, since the reac-
tion involves heat denaturation and therefore avoidance
of problems associated with secondary structure, it should
be possible to quantify miRNAs in a similar manner
to that achieved by the PCR-based assays, such as the
PE-PCR assay (10) and stem–loop RT-PCR (12).
In summary cqPCR enables; accurate measurement of
small amounts of siRNA in complex biological samples,
a simple, one-step procedure, an ability to measure only
intact siRNA thus avoiding degradation artefacts, and is
suitable for high throughput, using conventional qPCR
hardware and software (e.g. 96 or 384 well plate-based).
In addition, cqPCR avoids the minimum size constraints
for conventional qPCR template ampliﬁcation by utilizing
competition for primer binding as the quantiﬁed compo-
nent, rather than the number of template copies per se.
This is a new way of amplifying a signal by PCR, and
will help to ﬁll a gap in the repertoire of methods avail-
able for understanding siRNA biology with regard to
quantiﬁcation.
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